Paying users zone. Data is covered by .

  • Get to Bristol-Myers Squibb Co. for $15.99, or

  • get to whole website for at least 3 months from $49.99.

  2. Bristol-Myers Squibb Co.
  3. Statement of Financial Position, Assets
  4. Quarterly Data
 

$15.99

Bristol-Myers Squibb Co. (BMY)

Statement of Financial Position, Assets Quarterly Data

Difficulty: Beginner

The statement of financial position provides creditors, investors, and analysts with information on company's resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company's assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Bristol-Myers Squibb Co., Consolidated Statement of Financial Position, Assets (quarterly data)

USD $ in millions

 
Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014 Dec 31, 2013 Sep 30, 2013 Jun 30, 2013 Mar 31, 2013
Cash and cash equivalents
Marketable securities
Receivables
Inventories
Deferred income taxes
Prepaid expenses and other
Current assets
Property, plant and equipment
Goodwill
Other intangible assets
Deferred income taxes
Marketable securities
Other assets
Noncurrent assets
Total assets
Source: Bristol-Myers Squibb Co., Quarterly and Annual Reports
Item Description The company
Cash and cash equivalents Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits should not be reported as cash and cash equivalents. Bristol-Myers Squibb Co.'s cash and cash equivalents increased from Q3 2017 to Q4 2017 but then slightly declined from Q4 2017 to Q1 2018.
Marketable securities Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for less than one year or the normal operating cycle, whichever is longer. Bristol-Myers Squibb Co.'s marketable securities declined from Q3 2017 to Q4 2017 but then slightly increased from Q4 2017 to Q1 2018.
Inventories Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer). Bristol-Myers Squibb Co.'s inventories declined from Q3 2017 to Q4 2017 but then increased from Q4 2017 to Q1 2018 not reaching Q3 2017 level.
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co.'s current assets declined from Q3 2017 to Q4 2017 and from Q4 2017 to Q1 2018.
Property, plant and equipment Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, and production equipment. Bristol-Myers Squibb Co.'s property, plant and equipment declined from Q3 2017 to Q4 2017 but then increased from Q4 2017 to Q1 2018 exceeding Q3 2017 level.
Noncurrent assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co.'s noncurrent assets declined from Q3 2017 to Q4 2017 and from Q4 2017 to Q1 2018.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co.'s total assets declined from Q3 2017 to Q4 2017 and from Q4 2017 to Q1 2018.

Top

Stock Analysis on Net